Welcome to BioSeeker Group!

The Handbook on Alliances & Deals in Biotech Business

Additional Information

Published Date May 4, 2004
Pages 53
PDF Fact Sheet View Fact Sheet for the report The Handbook on Alliances & Deals in Biotech Business in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$495.00

Quick Overview

In the "Handbook on Alliances & Deals in Biotech Business" BioSeeker Group describes important structural issues for optimizing your deal value

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Handbook on Alliances & Deals in Biotech Business.

    To find out more about The Handbook on Alliances & Deals in Biotech Business, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Handbook on Alliances & Deals in Biotech Business is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

"The only way to win in this business is to have alliances, both for small companies and large ones." (Executive manager of a large biotech company). The number of new alliances has increased ten-fold within a 10 year period (1992-2001), from approximately 100 per year to close to 1000 per year today. In-licensing are becoming more and more important. Number of drugs that originated in-house has decreased from 80% in the 70th to only 40% in the beginning of 2000. If the pharmaceutical industry increased early deal prices substantially they would have a better chance economically. Several small companies have held back on out-licensing due to poor deal terms. Several evaluations of the relationship between deal value and developmental stage clearly demonstrate an unexpected small difference in values. These factors will drive the need for increased frequency and earlier stage deals.

There is still a large difference between in-licensing behaviors among the larger companies (BMS 53% and Eli Lilly 19%, year 2000). Over 10% of the approved in-licensed drugs have achieved blockbuster status whereas "only" approximately 5% of the internal drugs do so. According to estimations made by Wood Mackenzie’s licensing deals will up to 2010 grow to become the largest driver for big pharmaceutical companies. And expectations that almost 50% of revenues in major pharma will emerge from licensed compounds by 2005-2010. New collaborations are as likely to be made between two (small-large or large-large) biotechnology companies as they are between a biotechnology company and a pharmaceutical giant.

In the "Handbook on Alliances & Deals in Biotech Business" BioSeeker Group describes important structural issues for optimizing your deal value. Any management executive can use this strategic document as a guide of assistance in their tedious out-licensing efforts. Of outmost importance is the structure and time-line you work with. The most important issues to consider are discussed.

All biotechnology companies want to discover and develop treatments with a blockbuster potential. In addition, they want to be in charge of their products or services in the moneymaking process and to obtain every bit of revenue their product can convey. Realistically, almost no biotech company is ever going to have enough capital to achieve all of the steps needed. At the same time large pharmaceutical companies are more and more realizing the possibilities of future growth in revenues in the oncology field. Most of them do not have a strong pipeline and as well lack technology platforms, which force them to cover their needs by in-licensing or acquisitions. The licensing situation is changing. A stronger demand for earlier stage projects has become a reality since there is a dry for late stage projects. Doing business in the biotechnology arena changes constantly. And since many biotechnology companies must explore the possibilities for out-licensing product rights in the early hours in order to gain funds to maintain their existence or to move their pipeline products closer to commercialization they are dependent on constantly scanning the business climate. Most small company executives are more concerned about the time to sign the collaboration with a larger pharmaceutical company, to commercialize the product, than whom they are partnering with. Smaller pharmaceutical companies have introduced fresh technologies and new classes of drugs. The pharmaceutical companies are hungry for new products so, it is not difficult to come across various interesting associates. Knowledge of progress in drug discovery technologies and clinical trial design are as well of immense importance for keeping your company in the forefront, providing competitive advantage. And remember that a deal will send a clear signal to the investors!

A long list of key factors have to be considered. BioSeeker Group is confident that the choice of collaborator is more significant for success than the timing of the agreement. Using the cancer market as an example we structures and assesses important bullet-points you need in your deal making process. As well, provide several detailed descriptions of real case deal scenarios for your benchmarking.

The report includes

  • Description of the partnering process
  • Deal and partner strategies
  • Guide for increasing value on your pipeline
  • Identify your risk of missing good leads
  • Checkpoints for out-licensing
  • Real case scenarios

Executive summary
Introduction & Market Outlooks
Figure 1. Worldwide oncology market values of a selection of drug/therapy types in 2001 and 2000 (MUSD)
Table 1. Leading cancer drug sales (2001-2002).
Figure 2. Number of cancer drugs in clinical trials 1991-2001.
Table 2. BioSeeker Group structure of current cancer therapeutics.
Table 3. Therapeutic Strategies of a specific interest
Table 4. Novel approaches to cancer therapy.
Table 5. BioSeeker Group structure of future cancer therapeutics (mechanisms of action).
Historical FDA Approvals for Cancer Therapeutics
Alliances & Deal Values
Tools for deal making
Driving factors
Box 3. Bullet-points to increase value on your pipeline drugs.
Box 4. Checkpoints for out-licensing your project.
Determinants of deal prices
Table 6. Relation of perceptions of value driving factors.
Key factors for deal success
A key role in strategy
Table 7. Probabilities of success at differing development stages

A long list of issues to be considered!
What do the big pharma & biotech look for?
Novelty
Explore new areas
Do not think you know - Find out!

Validation & Activity
Get "expertise" comments on your science

Clinical issues
Several questions have to be addressed:
Present data frequently!

Approval and commercialization
Reimbursement issues
Improve your strategy for reimbursement:

Company issues
Describe your advantage in the competitive situation

Criteria in evaluating the fundamentals of a potential partner
The partnering process
Deal homework
Deal planning
Deal implementation

Hazards in your partnership
Real case scenarios
Case I: It has taken 20 years
Case II: New therapeutic strategy
Case III: Steady flow of licensing fees
Case IV: Early stage can be expensive
Case V: A success story
Case VI: Exchange money for market
Case VII: Revenues and credits
Case VIII: Up and down
Case IX: BioPharma mega deal
Case X: Continuous efforts - payoff?
Table 8. Overall structure of deals described in this section

Disclaimer
Liability
Completeness

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Handbook on Alliances & Deals in Biotech Business.
    To find out more about The Handbook on Alliances & Deals in Biotech Business, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Handbook on Alliances & Deals in Biotech Business is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Business Development' category:


Near Term Industry Analysis of US Therapeutic Discovery Programs: A Foretaste on What We can Expect from the US Life Science Industry in the Future
BioSeeker has created this analysis based on more than 2,800 companies and 4,500 projects covering 57 life science categories. Use this analysis to: Find technologies , drugs and devices of value to your company; Benchmark against competitors; Find trends in the current market place; Identify key personnel in companies and much more. Learn More


The Handbook on Alliances & Deals in Biotech Business
In the "Handbook on Alliances & Deals in Biotech Business" BioSeeker Group describes important structural issues for optimizing your deal value Learn More